- Home
- EAF vs XOMA Comparison
EAF vs XOMA Comparison
Compare EAF & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EAF
- XOMA
- Stock Information
- Founded
- EAF 1886
- XOMA 1981
- Country
- EAF United States
- XOMA United States
- Employees
- EAF N/A
- XOMA N/A
- Industry
- EAF Industrial Machinery/Components
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- EAF Energy
- XOMA Health Care
- Exchange
- EAF Nasdaq
- XOMA Nasdaq
- Market Cap
- EAF 335.5M
- XOMA 300.5M
- IPO Year
- EAF 1995
- XOMA N/A
- Fundamental
- Price
- EAF $1.17
- XOMA $24.05
- Analyst Decision
- EAF Hold
- XOMA Strong Buy
- Analyst Count
- EAF 7
- XOMA 2
- Target Price
- EAF $1.50
- XOMA $69.50
- AVG Volume (30 Days)
- EAF 2.3M
- XOMA 39.3K
- Earning Date
- EAF 07-25-2025
- XOMA 08-12-2025
- Dividend Yield
- EAF N/A
- XOMA N/A
- EPS Growth
- EAF N/A
- XOMA N/A
- EPS
- EAF N/A
- XOMA N/A
- Revenue
- EAF $514,037,000.00
- XOMA $42,909,000.00
- Revenue This Year
- EAF N/A
- XOMA $70.91
- Revenue Next Year
- EAF $26.22
- XOMA $14.00
- P/E Ratio
- EAF N/A
- XOMA N/A
- Revenue Growth
- EAF N/A
- XOMA 638.41
- 52 Week Low
- EAF $0.52
- XOMA $18.35
- 52 Week High
- EAF $2.53
- XOMA $35.00
- Technical
- Relative Strength Index (RSI)
- EAF 58.51
- XOMA 45.38
- Support Level
- EAF $1.10
- XOMA $23.51
- Resistance Level
- EAF $1.33
- XOMA $24.65
- Average True Range (ATR)
- EAF 0.12
- XOMA 1.10
- MACD
- EAF -0.00
- XOMA -0.17
- Stochastic Oscillator
- EAF 61.53
- XOMA 20.92
About EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.